Growth Metrics

Regeneron Pharmaceuticals (REGN) EBT Margin (2009 - 2026)

Regeneron Pharmaceuticals' quarterly EBT Margin came in at 23.05% in Q1 2026, down 683.0% year-on-year from 3.95% in Q1 2025, and down 14.2% quarter-over-quarter from 26.87% in Q4 2025.

Regeneron Pharmaceuticals has reported EBT Margin for 18 years, with the latest figure at 23.05% in Q1 2026.

  • For the quarter ending Q1 2026, EBT Margin fell 683.0% year-over-year to 23.05%; the trailing twelve-month figure through Mar 2026 stood at 34.56% (down 82.0% YoY), and the FY2025 full-year result was 36.47%, up 281.0% from the prior year.
  • EBT Margin for Q1 2026 stood at 23.05%, down from 26.87% in the prior quarter.
  • The five-year high for EBT Margin was 2122.2% in Q1 2022, with the low at 22.28% in Q1 2024.
  • Average EBT Margin over 5 years is 233.03%, with a median of 33.71% recorded in 2022.
  • Year-over-year, EBT Margin surged 207265 bps in 2022 and slumped 209507 bps in 2023.
  • Tracing REGN's EBT Margin over 5 years: stood at 1324.7% in 2022, then sank by 97 bps to 33.42% in 2023, then declined by 24 bps to 25.29% in 2024, then gained by 6 bps to 26.87% in 2025, then declined by 14 bps to 23.05% in 2026.
  • The last three EBT Margin figures came in at 23.05% (Q1 2026), 26.87% (Q4 2025), and 46.97% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.40%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 41.95%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 23.05%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 18.99%
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 23.05%
Dec 31, 2025 26.87%
Sep 30, 2025 46.97%
Jun 30, 2025 41.32%
Mar 31, 2025 29.88%
Dec 31, 2024 25.29%
Sep 30, 2024 40.13%
Jun 30, 2024 45.90%
Mar 31, 2024 22.28%
Dec 31, 2023 33.42%
Sep 30, 2023 33.03%
Jun 30, 2023 34.29%
Mar 31, 2023 27.13%
Dec 31, 2022 1,324.70%
Sep 30, 2022 51.42%
Jun 30, 2022 33.71%
Mar 31, 2022 2,122.20%
Dec 31, 2021 50.56%
Sep 30, 2021 52.61%
Jun 30, 2021 73.03%
Mar 31, 2021 49.55%
Dec 31, 2020 50.54%
Sep 30, 2020 43.52%
Jun 30, 2020 47.07%
Mar 31, 2020 36.57%
Dec 31, 2019 47.75%
Sep 30, 2019 44.07%
Jun 30, 2019 14.24%
Mar 31, 2019 39.79%
Dec 31, 2018 35.08%
Sep 30, 2018 38.23%
Jun 30, 2018 40.80%
Mar 31, 2018 38.73%
Dec 31, 2017 35.06%
Sep 30, 2017 37.69%
Jun 30, 2017 35.77%
Mar 31, 2017 32.77%
Dec 31, 2016 27.84%
Sep 30, 2016 29.99%
Jun 30, 2016 24.10%
Mar 31, 2016 27.49%
Dec 31, 2015 20.70%
Sep 30, 2015 34.58%
Jun 30, 2015 32.85%
Mar 31, 2015 31.80%
Dec 31, 2014 -3.93%
Sep 30, 2014 25.05%
Jun 30, 2014 31.37%
Mar 31, 2014 28.91%
Dec 31, 2013 29.68%
Sep 30, 2013 37.80%
Jun 30, 2013 32.27%
Mar 31, 2013 32.26%
Dec 31, 2012 32.45%
Sep 30, 2012 44.77%
Jun 30, 2012 25.21%
Mar 31, 2012 5.03%
Dec 31, 2011 -43.96%
Sep 30, 2011 -60.10%
Jun 30, 2011 -58.78%
Mar 31, 2011 -38.91%
Dec 31, 2010 111.94%
Sep 30, 2010 -686.28%
Jun 30, 2010 -21.98%
Mar 31, 2010 -1,618.35%
Dec 31, 2009 -309.18%
Sep 30, 2009 -0.86%
Jun 30, 2009 -331.96%